stockrow
Monday 9 November 2026
Export AYTU’s income statement to Excel — free account
Aytu BioPharma, Inc.
AYTUHealthcare Drug Manufacturers Specialty & Generic
Aytu BioPharma, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $57.6 million, down 13.3% from fiscal 2025.
- Revenue
- +6.42%
- EPS
- +100.0%
- Free cash flow
- +57.7%
- Total debt
- −21.9%
Quarter to June 2026, against a year earlier
1.83
0.02
+1.10%
Follow AYTU
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.46 | 0.51 | 0.42 | 0.28 | |
P/FCF ratio |
8.19 | 18.22 | 0.00 | 0.00 | |
P/Operating CF |
6.01 | (6.86) | 7.10 | (28.72) | |
P/B ratio |
0.75 | 0.82 | 1.84 | 0.77 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.30 | 0.42 | 0.27 | 0.19 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
5.25 | 14.18 | (28.57) | (9.01) | |
EV/FCF |
5.32 | 15.11 | (30.74) | (13.29) | |
Quick Ratio |
0.90 | 0.85 | 0.93 | 1.00 | |
Current Ratio |
1.13 | 1.12 | 1.16 | 1.23 | |
Net Debt/EBITDA |
(24.94) | 1.68 | 8.61 | 8.11 | |
Debt/Assets |
16.22% | 19.53% | 17.16% | 21.74% | |
Debt/Equity |
0.48 | 0.62 | 1.47 | 1.17 | |
Asset Turnover |
0.50 | 0.48 | 0.53 | 0.53 | |
Operating CF/Net income |
(293.73) | 0.74 | (0.35) | (0.31) | |
Capex/Depreciation |
(0.01) | 0.00 | (0.02) | 0.00 | |
Interest Coverage |
(2.03) | (9.32) | (3.52) | (2.91) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
64.73% | 87.84% | 72.98% | 73.78% | |
Intangible Assets out of Total Assets |
0.39 | 0.38 | 0.36 | 0.33 | |
Share Based Compensation of Revenue |
0.91% | 1.19% | 1.87% | 0.82% | |
Graham Net Nets |
(0.30) | (0.32) | (1.21) | (1.17) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(63.72%) | (157.14%) | (119.62%) | (102.66%) | |
Free Cash Flow Yield |
12.21% | 5.49% | (2.12%) | (5.21%) | |
Revenue per Share |
1.31 | 1.18 | 1.51 | 1.47 | |
Operating CF per Share |
0.36 | (0.40) | 0.37 | (0.07) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.36 | (0.40) | 0.36 | (0.07) | |
Cash per Share |
2.14 | 2.54 | 2.99 | 3.46 | |
Shareholders Equity per Share |
2.86 | 3.34 | 1.42 | 2.45 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.86 | 3.34 | 1.42 | 2.45 | |
Free Cash Flow |
4.39 | (4.18) | 3.66 | (0.62) | |
Working Capital |
7.10 | 7.35 | 10.68 | 15.12 | |
Capital Expenditures |
(0.01) | 0.00 | (0.02) | — | |
Net Current Asset Value |
(7.97) | (9.22) | (31.56) | (20.71) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
26.97 | 30.16 | 28.16 | 28.19 | |
Average Payables |
10.94 | 12.63 | 12.98 | 12.93 | |
Average Inventory |
9.15 | 9.26 | 9.87 | 10.92 | |
Average Assets |
114.59 | 117.95 | 119.11 | 120.41 | |
Average Common Equity |
27.12 | 35.02 | 22.48 | 26.50 |
Columns are period end dates · fundamentals updated 2 Nov 2026